| Literature DB >> 31882709 |
Sofia Edin1, Tuomas Kaprio2,3, Jaana Hagström3,4, Pär Larsson5, Harri Mustonen2,3, Camilla Böckelman2,3, Karin Strigård6, Ulf Gunnarsson6, Caj Haglund2,3, Richard Palmqvist5.
Abstract
The anti-tumour immune response is critical to patient prognosis in colorectal cancer (CRC). The aim of this study was to investigate infiltration of B lymphocytes into CRC tumours, and their clinical relevance, prognostic value and relation to other immune cell subsets. We used multiplexed immunohistochemistry and multispectral imaging to assay the amount of infiltrating CD20+ B lymphocytes along with infiltration of CD8+ cytotoxic T cells, FOXP3+ T regulatory cells, CD68+ macrophages and CD66b+ neutrophils, in 316 archival CRC tissue specimens. A higher density of infiltrating CD20+ B lymphocytes was associated with tumours of the right colon (P = 0.025) and of lower stages (P = 0.009). Furthermore, patients whose tumours were highly infiltrated by CD20+ B lymphocytes had a significantly improved disease-specific survival (HR = 0.45, 95% CI 0.28-0.73, P = 0.001), which remained significant in multivariable analysis. CD20+ B lymphocytes were highly and positively associated with CD8+ T lymphocytes (P < 0.001), and part of the prognostic role was found to be a cooperative effect between these lymphocyte subsets. Our results support a favourable prognostic value of tumour-infiltrating CD20+ B lymphocytes in CRC. Furthermore, a cooperative prognostic effect between CD20+ B lymphocytes and CD8+ T lymphocytes is suggested.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31882709 PMCID: PMC6934737 DOI: 10.1038/s41598-019-56441-8
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Multispectral imaging of immune cell infiltrates in CRC tissues. (a) A high-magnification area (20x) of a representative multiplexed IHC stained composite image after imaging and spectral unmixing (left panel), after tissue segmentation into tumour (magenta) and stromal (blue) compartments (middle panel), and after cell phenotyping (right panel). The following colors were used to identify the different markers; pan-Cytokeratin (magenta), CD20 (yellow), CD8 (red), CD66b (green), CD68 (cyan), FoxP3 (orange), and DAPI (blue). (b) Illustrates the staining pattern of the individual markers on a high-resolution area of a representative TMA core, after spectral unmixing, using the pathology view tool. (c) Histograms displaying the distribution (number of cells per mm2) of infiltrating immune cell subsets in the cohort of 275 CRC patients. In addition, the normal curve and the median number of infiltrating cells is shown.
Associations to clinicopathological characteristics.
| Stromal CD20 | ||||
|---|---|---|---|---|
| Low | High | |||
| 275 | 138 (50.2) | 137 (49.8) | ||
| 4.4 (±4.8) | 255.1 (±516.3) | |||
| ≤59 | 74 | 36 (48.6) | 38 (51.4) | 0.964/0.703* |
| 60–69 | 73 | 37 (50.7) | 36 (49.3) | |
| 70–79 | 83 | 41 (49.4) | 42 (50.6) | |
| ≥80 | 45 | 24 (53.3) | 21 (46.7) | |
| Women | 132 | 64 (48.5) | 68 (51.5) | 0.589 |
| Men | 143 | 74 (51.7) | 69 (48.3) | |
| Right-sided colon | 73 | 29 (39.7) | 44 (60.3) | 0.080/0.025* |
| Left-sided colon | 55 | 27 (49.1) | 28 (50.9) | |
| Rectum | 147 | 82 (55.8) | 65 (44.2) | |
| I | 55 | 20 (36.4) | 35 (63.6) | 0.009/0.009* |
| II | 77 | 41 (53.2) | 36 (46.8) | |
| III | 95 | 44 (46.3) | 51 (53.7) | |
| IV | 48 | 33 (68.8) | 15 (31.3) | |
| No | 227 | 101 (44.5) | 126 (55.5) | <0.001 |
| Yes | 48 | 37 (77.1) | 11 (22.9) | |
χ2 tests were used for categorical variables. *Exact linear-by-linear association test was used to test for linear relationship between variables. †Preoperative radiation therapy in rectal cancers only.
The correlation of infiltration of CD20 positive cells in the stromal compartment to infiltration of other immune cell markers.
| Immune marker | CD20 | CD20 |
|---|---|---|
| Stromal CD8 | 0.568 | <0.001 |
| Tumour CD8 | 0.403 | <0.001 |
| Stromal CD66b | 0.234 | <0.001 |
| Tumour CD66b | 0.184 | 0.002 |
| Stromal CD68 | 0.219 | <0.001 |
| Stromal FOXP3 | 0.237 | <0.001 |
rs, Spearmans rank correlation coefficient. Analyses were performed using continuous values for number of cells/mm2 (n = 275).
Figure 2Disease-specific survival in CRC according to infiltration of CD20+ cells. High or low infiltration of stromal CD20 in CRC cases (a), in non-irradiated CRC cases (b), and in irradiated rectal cancers (c). Shown are Kaplan-Meier plots. Log-rank tests were used to calculate P-values.
Cox regression analyses of infiltrating immune cells in predicting survival of CRC patients.
| Immune marker | univariable | multivariablea | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | HR | 95% CI | |||
| Stromal CD20 | 0.45 | 0.28–0.73 | 0.001 | 0.60 | 0.37–0.99 | 0.045 |
| Stromal CD8 | 0.32 | 0.20–0.53 | <0.001 | 0.42 | 0.25–0.72 | 0.002 |
| Tumour CD8 | 0.31 | 0.19–0.51 | <0.001 | 0.54 | 0.33–0.90 | 0.018 |
| Stromal CD66b | 0.60 | 0.38–0.96 | 0.033 | 0.73 | 0.45–1.17 | 0.189 |
| Tumour CD66b | 0.47 | 0.29–0.75 | 0.002 | 0.56 | 0.34–0.92 | 0.022 |
| Stromal CD68 | 0.38 | 0.23–0.62 | <0.001 | 0.55 | 0.31–0.96 | 0.034 |
| Stromal FoxP3 | 0.31 | 0.19–0.51 | <0.001 | 0.75 | 0.43–1.31 | 0.318 |
aThe Cox regression multivariable models included one categorical immune parameter, age, localisation and stage, and were stratified by sex (n = 217). Abbreviations: HR, hazard ratio; CI, confidence interval.
Prognostic relations of immune cell subsets in CRC.
| Immune marker | univariable | multivariablea | ||||||
|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | HR | 95% CI | |||||
| Stromal CD20/Stromal CD8 | High/High (ref) | 97 | 1.00 | — | 1.00 | — | ||
| High/Low (1) | 29 | 3.83 | 1.85–7.95 | <0.001 | 3.36 | 1.54–7.34 | 0.002 | |
| Low/High (2) | 33 | 2.28 | 1.03–5.08 | 0.043 | 2.05 | 0.91–4.61 | 0.084 | |
| Low/Low (3) | 68 | 4.06 | 2.20–7.48 | <0.001 | 2.87 | 1.49–5.51 | 0.002 | |
| Stromal CD20/Stromal CD66b | High/High (ref) | 76 | 1.00 | — | 1.00 | — | ||
| High/Low (1) | 50 | 1.55 | 0.75–3.21 | 0.240 | 1.54 | 0.73–3.24 | 0.259 | |
| Low/High (2) | 49 | 2.11 | 1.07–4.15 | 0.031 | 1.86 | 0.92–3.78 | 0.086 | |
| Low/Low (3) | 52 | 3.37 | 1.76–6.43 | <0.001 | 2.13 | 1.09–4.14 | 0.027 | |
| Stromal CD20/Stromal CD68 | High/High (ref) | 73 | 1.00 | — | 1.00 | — | ||
| High/Low (1) | 53 | 3.45 | 1.57–7.58 | 0.002 | 3.27 | 1.41–7.59 | 0.006 | |
| Low/High (2) | 44 | 2.96 | 1.28–6.83 | 0.011 | 3.32 | 1.40–7.87 | 0.006 | |
| Low/Low (3) | 57 | 5.59 | 2.64–11.82 | <0.001 | 3.38 | 1.49–7.67 | 0.004 | |
| Stromal CD20/Stromal FoxP3 | High/High (ref) | 74 | 1.00 | — | 1.00 | — | ||
| High/Low (1) | 52 | 3.10 | 1.46–6.57 | 0.003 | 1.34 | 0.60–3.02 | 0.476 | |
| Low/High (2) | 43 | 2.03 | 0.90–4.61 | 0.089 | 1.74 | 0.74–4.08 | 0.201 | |
| Low/Low (3) | 58 | 5.80 | 2.91–11.58 | <0.001 | 2.11 | 0.99–4.50 | 0.053 | |
aThe Cox regression multivariable models included one categorical immune parameter, age, localization and stage, and were stratified by sex. Abbreviations: HR, hazard ratio; CI, confidence interval.
Figure 3Prognostic relation of CD20+ cells to different immune cell subsets in CRC. Cases scored for subgroups of CD20 high or low together with; (a) CD8 high or low; (b) CD66b high or low; (c) CD68 high or low; and (d) FoxP3 high or low, in the tumour stromal compartment as indicated. Shown are Kaplan-Meier plots. Log-rank tests were used to calculate P-values.